Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ipratropium bromide
- Development stage
- Approved
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules
- Administration
- Inhalation, Intranasal
01
Overview
Ipratropium bromide is a quaternary ammonium anticholinergic bronchodilator used primarily for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, as well as for asthma symptom control. It acts as a nonselective muscarinic acetylcholine receptor antagonist, blocking cholinergic influences on bronchial smooth muscle to induce bronchodilation and reduce mucus secretion. Due to its quaternary amine structure, it does not cross the blood–brain barrier, minimizing central side effects. It is administered mainly by inhalation for local effect in the lungs[1][2][3][7][10].
- Brand names
- AtroventAlti-IpratropiumApo-IpraventIpratropium Bromide NebuampIpratrovent SterulesRatio-IpratropiumRatio-Ipratropium UdvApoventIpraxaRinatec
- Other names
- 溴化异丙托品 (Chinese)异丙托溴铵 (Chinese)bromuro de ipratropio
02
Targets
M1 (Muscarinic acetylcholine receptor M1)CHRM3 (M3)CHRM2 (M2)
Beyond the preview
Go deeper on ipratropium bromide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ipratropium bromide.